+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Benign Prostatic Hyperplasia Treatment Market 2019-2025

  • ID: 5129900
  • Report
  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • ProArc Medical, Ltd.
Global Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report, by Treatment (Medications {Alpha-blockers, 5 Alpha reductase inhibitor (ARIs), Phosphodiesterase-5 Enzyme Inhibitor, and Others}, Minimally Invasive Procedures {TURP, TUIP, TUMT, and TUNA}, Laser Therapy {Ablative procedures and Enucleation procedures}, and Others) and Forecast Period 2019-2025.

The global benign prostatic hyperplasia treatment market is estimated to grow at a significant CAGR during the forecast period. The rising frequency of benign prostatic hyperplasia among middle-aged people is driving the market. BPH affects nearly 50% of men between the ages of 51-60 and 90% of men age above 80. Moreover, some crucial factors attributing to the positive growth of the market, that are economic growth and public & government awareness. The US health advocate and health authorities conduct prostate health awareness campaign the “National Prostate Health Month” every year in September, to educate the people about the risk and treatment that are associates with benign prostatic hyperplasia.

The global benign prostatic hyperplasia treatment market is segmented based on treatment type. Based on the treatment type, the market is segmented into medications, minimally invasive procedures, laser therapy, and others. Based on medications, it is segmented into alpha-blockers, 5 alpha-reductase inhibitors (ARIs), a phosphodiesterase-5 enzyme inhibitor, and others. Based on minimally invasive procedures, it is segmented into transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), and Transurethral Needle Ablation (TUNA). Based on laser therapy, it is segmented into ablative procedures and enucleation procedures. Based on geography, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and RoW.

The key players providing benign prostatic hyperplasia treatment products include Allergan PLC, Eli Lilly, and Co., Merck & Co., Inc., Abbott Laboratories, Allergan, Inc., Astellas Pharma, Inc., Pfizer, Inc., Sanofi S.A., Karl Storz GmbH& Co.Kg, Lumenis,Ltd., Olympus Corporation, Boston Scientific Corp., and others. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance, in May 2019, Lumenis Ltd. launched MOSES for BPH procedures. This device optimizes holmium energy transmission using pulse modulation. This technology also added to Holmium Laser Enucleation of the Prostate (HoLEP)

Research Methodology

The market study of the global benign prostatic hyperplasia treatment market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Reports of companies involved in the market
  • Authentic public databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog
The report is intended for providers, suppliers, and distributors of benign prostatic hyperplasia treatment, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

The Report Covers:
  • Comprehensive research methodology of the global benign prostatic hyperplasia treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global benign prostatic hyperplasia treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • ProArc Medical, Ltd.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusions

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Allergan PLC
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Eli Lilly and Company
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Merck & Co., Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Lumenis, Ltd.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Olympus Corp.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
3.3.6. Karl Storz GmbH& Co.Kg
3.3.6.1. Overview
3.3.6.2. Financial Analysis
3.3.6.3. SWOT Analysis
3.3.6.4. Recent Developments

4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities

5. Market Segmentation
5.1. Global Benign Prostatic Hyperplasia Treatment Market by Treatment
5.1.1. Medications
5.1.1.1. Alpha-blockers
5.1.1.2. 5 Alpha reductase inhibitor (ARIs)
5.1.1.3. Phosphodiesterase-5 Enzyme Inhibitor
5.1.1.4. Others
5.1.2. Minimally Invasive Procedures
5.1.2.1. Transurethral Resection of the Prostate (TURP)
5.1.2.2. Transurethral Incision of the Prostate (TUIP)
5.1.2.3. Transurethral Microwave Thermotherapy (TUMT)
5.1.2.4. Transurethral Needle Ablation (TUNA)
5.1.3. Laser Therapy
5.1.3.1. Ablative procedures
5.1.3.2. Enucleation procedures
5.1.4. Others (Surgery, Prosthetic urethral lift, Embolization)

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Abbott Laboratories
7.2. Allergan, Inc.
7.3. Astellas Pharma, Inc.
7.4. Boehringer Ingelheim GmbH
7.5. Boston Scientific Corp.
7.6. Camber Pharmaceuticals, Inc.
7.7. Coloplast A/S
7.8. Daiichi Sankyo Co., Ltd.
7.9. Eli Lilly &Co.
7.10. Endo International PLC
7.11. GlaxoSmithKline PLC
7.12. Karl Storz GmbH& Co.Kg
7.13. Lumenis, Ltd.
7.14. Merck & Co., Inc.
7.15. Nymox Pharmaceutical Corp.
7.16. Olympus Corp.
7.17. Pfizer, Inc.
7.18. ProArc Medical, Ltd.
7.19. Sanofi S.A.
7.20. Sophiris Bio Corp.
7.21. Sun Pharmaceutical Industries, Ltd.
7.22. Synthon B.V.
7.23. Teva Pharmaceutical Industries, Ltd.
7.24. Urologix, Inc.
7.25. Veru, Inc.
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Allergan, Inc.
  • Astellas Pharma, Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corp.
  • Camber Pharmaceuticals, Inc.
  • Coloplast A/S
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly & Co.
  • Endo International PLC
  • GlaxoSmithKline PLC
  • Karl Storz GmbH& Co.Kg
  • Lumenis, Ltd.
  • Merck & Co., Inc.
  • Nymox Pharmaceutical Corp.
  • Olympus Corp.
  • Pfizer, Inc.
  • ProArc Medical, Ltd.
  • Sanofi S.A.
  • Sophiris Bio Corp.
  • Sun Pharmaceutical Industries, Ltd.
  • Synthon B.V.
  • Teva Pharmaceutical Industries, Ltd.
  • Urologix, Inc.
  • Veru, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll